PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

REPEAT: MARKET COMMENT: FTSE 100 Closes Up For Sixth Day, Third Week In A Row

Fri, 21st Feb 2014 17:14

LONDON (Alliance News) - The FTSE 100 closed higher for the sixth consecutive day Friday, closing less than 100 points short of its 2014 opening level as investors shrugged off a host of weaker-than-expected UK and US data releases to ensure the global equity rally continues.

The FTSE 100 closed up 0.4% at 6,838.06, which means the blue-chip index has now ended the week higher than it started it for the third week in a row. The FTSE 250 closed up 0.6% at 16,460.88, while the AIM All-Share index snapped an 11-day winning streak closing down 0.2% at 881.6.

Positive sentiment was evident across the world Friday, with the CAC 40 in Paris closing up 0.6%, the DAX 30 in Frankfurt closing up 0.5%, and Asian equities closing broadly higher earlier in the day, with the excepted of the Shanghai Composite index.

In the US, at the close of the London equity market, the DJIA and S&P 500 are both up 0.3%, with the NASDAQ Composite up 0.4%.

British retail sales declined at the sharpest pace since 2012 in January, as food sales weakened noticeably after Christmas, data from the Office of National Statistics revealed. Retail sales volume, including automotive fuel, fell 1.5% month-on-month in January, which was the first decline in three months and the biggest since April 2012. Economists had expected the sales to fall by 1%, following a 2.5% rise in December.

Despite this, the latest decline has to be viewed in the context of the surge in sales in December and the very wet weather experienced in January, which will have deterred consumers from venturing to the shops, said James Knightley, economist at ING Bank NV.

Forex.com's research director Kathleen Brooks added: "The good news for British retailers is that despite this month-on-month fall, the quantity bought still remains strong, and the underlying trend in the data, suggested by the three month-on-three month growth rate for retail sales, actually increased by 1.1% in January, thus confirming strong momentum in consumption."

Nevertheless, food store sales slipped 3.4% in January, with non-food store sales gaining 0.4%.

In a separate report, released at the same time, UK public sector net borrowing declined by GBP6.43 billion in January, down from a revised GBP9.03 billion rise in December. Consensus expectations were for a fall to GBP9.00 billion.

The pound, which had been sold in the run-up to the data, jumped to regain its losses in the aftermath, before slipping again late in the day. At the close of the UK equity markets, sterling trades at EUR1.2123 and CHF1.4798.

The currency pushed even higher against the dollar later in the trading session as home sales data from the world's largest economy disappointed.

The National Association of Realtors revealed that sales of previously owned homes fell 5.1% in January to an annual rate of 4.62 million. Economists had expected the rate of sales to come in at 4.68 million, down 4.3%.

The data caused the dollar to drop against its major rivals, before it regained some of its strength later in the session. At the London stock market close, the pound trades at USD1.6641, the euro at USD1.3723, and the Swiss franc at USD1.1247.

At the individual stock level, Royal Bank of Scotland Group, closing up 1.8%, was among the leading gainers in the FTSE 100. The Financial Times quoted people familiar with the banks plans saying it is preparing a dramatic retrenchment that would see it become a much smaller UK retail and commercial bank. The restructuring will form part of a series of cost-cutting measures and disposals led by new Chief Executive Ross McEwan, and is expected to see staff numbers slashed by at least 30,000 in the coming years, the paper said.

Following the report, Shore Capital reiterated its Buy recommendation, saying that the move is likely to result in a, "smaller but more efficient, higher return and less risky bank."

The company was outperformed by Vodafone, however, which closed up 3%. US blue-chip Verizon Communications said Friday that it has completed its acquisition of Vodafone's 45% indirect interest in Verizon Wireless in a transaction valued at about USD130 billion. As previously announced, Verizon issued about 1.27 billion common shares to shareholders of Vodafone as the stock portion of the consideration for Vodafone's 45% indirect interest in Verizon Wireless.

GlaxoSmithKline, closing up 0.3%, was also a gainer after it said Incruse, a treatment for chronic obstructive pulmonary disease, had been recommended for marketing authorisation by the European Medicines Agency's committee for Medical Products for Human Use, a key step in getting approval for the drug.

In the FTSE 250, IP Group ended the day as the index's second-biggest gainer, up 3.7%. The group's share price jumped after it said that its portfolio company, Xeros Ltd, intends to float on AIM to raise funds to bring its patented polymer bead cleaning system to the laundry market.

Millennium & Copthorne Hotels, closing up 3.3%, was another of the index's biggest winners after it reported higher revenues and profits for 2013, even though the improvements were due to a one-off profit boost from its Glyndebourne property development in Singapore at the end of the fourth quarter, and it cautioned that its room refurbishment programme would continue to weigh on its results this year.

The group's revenue increased to the record level of GBP1.04 billion in 2013, due to a GBP273.7 million revenue boost from the Glyndebourne development in Singapore, with pretax profit rising to GBP263.6 million in the year, up from GBP171.3 million in 2012.

Meanwhile, in the AIM All-Share index, The Real Good Food Company closed down 26% after it said it is in a pricing dispute with Associated British Foods' British Sugar unit, a major supplier to Real Good Food's Napier Brown non-refining sugar distribution business.

The group has complained to the Office of Fair Trading that British Sugar is charging too much and abusing its dominant position in the UK sugar market. It said the dispute is unlikely to be quickly resolved and will weigh on its results this year and next.

In the data calendar Monday, German IFO business climate data are released at 0900 GMT, ahead of EU consumer price inflation data for January at 1000 GMT.

In the US, the Chicago Federal Reserve releases its national activity index at 1330 GMT. US Markit services PMI is released at 1358 GMT, with the Dallas Fed publishing the Texas manufacturing outlook survey at 1530 GMT.

In the corporate calendar, FTSE 100-constituent Bunzl is joined by FTSE 250-listed Bovis Homes and Hiscox in releasing full-year results for 2013 ahead of the London stock market open. The blue-chip index's largest company by market capitalization, HSBC Holdings, releases its full-year results at 0815 GMT.

Meanwhile, Associated British Foods releases a trading statement.

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.